Burnaby firm receives federal funding to develop oral COVID vaccine – Enterprise Information

Burnaby company receives federal funding to develop oral COVID vaccine - Business News

Oral vaccine work

Chris Campbell / Burnaby Now – | History: 340404

Photo: Symvivo

A Burnaby company is receiving federal agency consultancy services and up to $ 4.57 million in research and development funding to help develop an orally administered COVID-19 vaccine.

Symvivo Corporation announced that the National Research Council of Canada’s Industrial Research Assistance Program will help advance the clinical development of bacTRL-Spike, the company’s orally administered vaccine candidate for the prevention of COVID-19, and expand the bacTRL platform to include to support additional vaccine goals.

“This is an important step in the development of orally administered vaccines against COVID-19 and other major infectious diseases, both now and in the future. We are very excited to continue this important work with the support of NRC IRAP, ”said Alexander Graves, CEO of Symvivo Corporation, in a statement.

The funding follows an earlier R&D project funded by the NRC IRAP that enabled the development and initial clinical evaluation of Symvivo’s bacTRL spike vaccine candidate, which has met the necessary scientific and technical requirements for advancement.

BacTRL-Spike is the company’s oral DNA vaccine candidate for the prevention of COVID-19.

Unlike traditional vaccines, which are given by intramuscular injection, bacTRL-Spike is taken orally, giving individuals the option to self-administer the vaccine.